FDA Roundup: August 29, 2023

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
- On Monday, the FDA informed consumers in Treating and Dealing with ADHD about FDA-approved treatments to help reduce the symptoms of attention-deficit/hyperactivity disorder, also known as ADHD, and improve functioning in children as young as age 6 years old.
- On Friday, the American Dental Association Science and Research Institute, the University of Pittsburgh School of Dental Medicine, and the Center for Integrative Global Oral Health at the University of Pennsylvania School of Dental Medicine issued a new clinical practice guideline detailing dental pain management strategies for children. The development of this guideline was funded by an FDA-provided grant. An FDA-commissioned report by the National Academies of Science, Engineering, and Medicine recommended that the guideline be developed.
- On Friday, the Interagency Food Safety Analytics Collaboration (IFSAC) — a collaboration between the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), and the USDA Food Safety and Inspection Service (FSIS) — published its upcoming priorities for calendar years 2024 – 2028.
Tags
Animal & Veterinary
Award
Biologics
Coronavirus
Cosmetics
Dietary Supplements
Drugs
Follow @FDAmedia on Twitter
Follow @FDAMedia on X
Follow @US_FDA on Twitter
Follow @US_FDA on X
Follow FDA on Facebook
Food & Beverages
Infant Formula & Foods
Infectious Disease
Medical Devices
Office
Over-the-Counter Drugs
Press Announcements
Tobacco
Training
Vaccines